ReviewFrontiers in neuroscience2026
Metabolic syndrome and perioperative neurocognitive disorders: epidemiology, mechanisms, and interventions.
Review in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perioperative neurocognitive disorders, an umbrella term encompassing preoperative cognitive impairment, acute postoperative delirium, and longer term postoperative neurocognitive disorders, represent significant complications for the growing population of older surgical patients. The rising prevalence of metabolic syndrome, defined by the clustering of abdominal obesity, insulin resistance, hypertension, and dyslipidemia, necessitates a deeper understanding of its impact on the perioperative brain. This comprehensive review elucidates the intricate epidemiological and mechanistic links between metabolic syndrome and the spectrum of cognitive decline. Epidemiologically, we disaggregate the risk profiles of individual components, demonstrating that distinct metabolic phenotypes serve as specific predictors for different phases of impairment. Mechanistically, we propose a sequential pathophysiological cascade where chronic systemic inflammation primes the brain for injury. Surgical stress triggers the failure of a compromised blood brain barrier, leading to the activation of the TLR4/NLRP3 inflammasome and the induction of central insulin resistance. These processes ultimately culminate in mitochondrial energy crises and synaptic degradation. To address these vulnerabilities, we evaluate an integrated perioperative strategy spanning preoperative metabolic optimization, intraoperative management, and emerging pharmacological interventions such as SGLT2 inhibitors and mitochondria targeted antioxidants. Critically, this review identifies a major knowledge gap regarding the absence of dedicated randomized controlled trials targeting the surgical metabolic syndrome population. Ultimately, our findings advocate for a clinical paradigm shift toward phenotype specific metabolic optimization to improve neurocognitive outcomes in these high risk patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.